Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial.

Lara PN, Longmate J, Stadler W, van Loan M, Wexler J, Quinn DI, Twardowski P, Vokes EE, Gandara DR. Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial. J Clin Oncol. 2005 Jun; 23(16_suppl):4569.

View in: PubMed

collapse authors with profiles